Actimed Therapeutics’ Company participation and panel discussion at LSX World Congress 2022
London, UK - 12 May 2022. Actimed Therapeutics Ltd, the clinical stage company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders was pleased to participate at the 8th Annual LSX World Congress 2022. The Company’s CEO, Robin Bhattacherjee presented Actimed during the Company Presentation section at the Congress and participated in the panel discussion on ‘Preparing for and Protecting your Assets when Entering the US’.
Robin presented on recent developments at Actimed as it works towards its Phase 2b/3 clinical trials for its lead candidate S-pindolol benzoate (ACM-001.1) for treatment of cancer cachexia. The company continues to advance its pharmacokinetics and pharmacodynamics (PK/PD) study for S-pindolol benzoate (ACM-001.1) with data from this study expected in the first half of 2022. Actimed is also planning the further development of S-oxprenolol for the treatment of Amyotrophic Lateral Sclerosis (ALS).
The panel discussion addressed key strategic considerations for early-stage companies targeting the US and international markets, involving varied insight from respresentives of pharmaceutical company, Eli Lilly and biotech company Mogrify. This included asset protection for new market entry and the key steps to optimising company intellectual property portfolios for long-term success. This discussion follows the Company’s recent strengthening of its intellectual property portfolio with its new UK patent (GB 2593902) covering new salts of S-pindolol for the use in the treatment or prevention of cachexia for which an international PCT filing has also been made.
Robin Bhattacherjee, CEO commented, “It was a privilege to attend this year’s LSX World Congress to discuss the positive progress Actimed has made over the past year, as we seek to bring groundbreaking new treatments to patients suffering with cachexia and ALS. The grant of a new patent for S-pindolol benzoate has significantly strengthened our global intellectual property portfolio and follows the grant of a US patent for S-pindolol for treatment of muscle weakness and a Canadian patent for S-oxprenolol for treatment of ALS. Along with the initiation of our first clinical study for S-pindolol benzoate, these latest developments are important milestones in our vision to develop one of the first globally approved products to treat cancer cachexia and impact significantly on patients’ lives.”
About Actimed Therapeutics
Actimed Therapeutics is a clinical stage biopharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders to transform the care of an underserved and vulnerable patient population. Actimed was founded in 2017 by Stefan Anker and Andrew Coats, two world leading physicians in muscle wasting research.
The lead area of focus for Actimed is specifically in cachexia. Cachexia is a wasting disease that accompanies cancer and other serious chronic illnesses and is associated with significant morbidity and mortality. Despite its prevalence and devastating clinical effects, there is no globally approved drug for the treatment or prevention of cancer-related cachexia.
It has been estimated that cachexia affects 50–80% of cancer patients and accounts for up to 20% of cancer deaths. Treating cancer cachexia successfully may increase both the length and quality of life for cancer patients.
The lead product of Actimed, S-pindolol benzoate (ACM-001.1) targets multiple pathways that drive cachexia and has generated promising proof of concept Phase II clinical data in cachexia patients. Actimed is currently preparing for further clinical studies in cachexia in Non-Small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC).
Actimed has also licensed the global rights to develop and commercialise S-oxprenolol, for cancer cachexia and any other indications outside of amyotrophic lateral sclerosis (ALS) to Faraday Pharmaceuticals. Actimed retains global rights to S-oxprenolol in ALS, where loss of body mass and muscle wasting may impact survival.
About LSX World Congress
LSX World Congress gathers the founders and CEOs of innovative start-ups through to healthcare giants, and everyone in between. It represents the breadth and depth of the cutting-edge research and technology driving the advances in the industry right now and in the near future.
It is an industry-leading gathering with qualified 1:1 partnering at its core, connecting the biotech, healthtech and medtech industry c-suite with the sector’s most active pharma, investors and health technology BD&L teams, R&D leaders, KOLs alongside top tier service companies who are driving the sector forward.